Last update 25 Oct 2025

Anti-CD19 CAR T cell therapy(University of Erlangen-Nürnberg Medical School)

Overview

Basic Info

Drug Type
CAR-T
Synonyms-
Target
CD19
Action
modulators
Mechanism
CD19 modulators(B-lymphocyte antigen CD19 modulators)
Therapeutic Areas
Immune System DiseasesNervous System DiseasesSkin and Musculoskeletal Diseases+ [1]
Active Indication
DermatomyositisScleroderma, SystemicSystemic Lupus Erythematosus
Inactive Indication-
Originator Organization
Friedrich Alexander Universität Erlangen NürnbergFriedrich Alexander Universität Erlangen Nürnberg
Active Organization
Miltenyi Biomedicine GmbHMiltenyi Biomedicine GmbH
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Anti-CD19 CAR T cell therapy(University of Erlangen-Nürnberg Medical School)
NCT06347718
/ RecruitingPhase 1/2
CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease
100 Clinical Results associated with Anti-CD19 CAR T cell therapy(University of Erlangen-Nürnberg Medical School)
Login to view more data
100 Translational Medicine associated with Anti-CD19 CAR T cell therapy(University of Erlangen-Nürnberg Medical School)
Login to view more data
100 Patents (Medical) associated with Anti-CD19 CAR T cell therapy(University of Erlangen-Nürnberg Medical School)
Login to view more data
100 Deals associated with Anti-CD19 CAR T cell therapy(University of Erlangen-Nürnberg Medical School)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
DermatomyositisPhase 2
Germany
Miltenyi Biomedicine GmbHMiltenyi Biomedicine GmbH
17 Jul 2023
Scleroderma, SystemicPhase 2
Germany
Miltenyi Biomedicine GmbHMiltenyi Biomedicine GmbH
17 Jul 2023
Systemic Lupus ErythematosusPhase 2
Germany
Miltenyi Biomedicine GmbHMiltenyi Biomedicine GmbH
17 Jul 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT06347718 (CASTLE, EULAR 12024 | EULAR 22024)
ManualManual
Phase 1/2
Rheumatic Diseases
8
xocsdqxfbh(lzjwsysnqw) = No higher grade CRS (grade 3 or 4) was observed (grade 0: N=3; grade 1: N=4; grade 2: N=1). vahksymhny (kyvfvqamhn )
View more
Positive
12 Jun 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free